Assets (2 total) 2 Total Assets
1 Approved
1 Phase 3 / Filed
0 Phase 1–2 / Early
5 Diseases
Disease: All diseases (2) Major Depressive Disorder (1) Schizophrenia (1) Bipolar Depression (1) Alzheimer's Disease (1) Generalized Anxiety Disorder (1)
Stage: All stages (2) Approved / Phase 4 (1) Phase 3 / Filed (1) Phase 2 Phase 1 / Preclinical
Quick filter: All (2) Major Depressive Disorder (1) Schizophrenia (1) Bipolar Depression (1) Alzheimer's Disease (1) Generalized Anxiety Disorder (1)
Showing 2 of 2 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Approved Serotonin 5-HT2A / dopamine D1-D2 receptor Small molecule
Major Depressive Disorder Schizophrenia Bipolar Depression
Phase 3 Serotonin 5-HT2A / dopamine D1-D2 receptor Small molecule
Alzheimer's Disease Generalized Anxiety Disorder
Alzheimer's Disease Agitation
Upcoming events (12 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2027 (6) March 2027 (1) Deulumateperone Phase 2 Generalized Anxiety Disorder Est. primary completion 2027-03-16 ·
NCT06480383 ·
CT.gov ↗ What to watch
April 2027 (1) June 2027 (2) Lumateperone · Caplyta Phase 3 Irritability Associated With Autism Spectrum Disorder Est. primary completion 2027-06-21 ·
NCT06690398 ·
CT.gov ↗ What to watch
Lumateperone · Caplyta Phase 3 Irritability Associated With Autism Spectrum Disorder Est. primary completion 2027-06-21 ·
NCT06706674 ·
CT.gov ↗ What to watch
October 2027 (1) Deulumateperone Phase 2 Generalized Anxiety Disorder Est. primary completion 2027-10-14 ·
NCT06701903 ·
CT.gov ↗ What to watch
December 2027 (1) Deulumateperone Phase 2 Agitation Associated With Alzheimer's Dementia Est. primary completion 2027-12-28 ·
NCT06651567 ·
CT.gov ↗ What to watch
2028 (1) September 2028 (1) Deulumateperone Phase 2 Psychotic Disorders, Alzheimer Disease Est. primary completion 2028-09-30 ·
NCT06540833 ·
CT.gov ↗ What to watch
2029 (1) 2030 (2) February 2030 (1) Deulumateperone Phase 3 Generalized Anxiety Disorder Est. primary completion 2030-02-18 ·
NCT07807865 ·
CT.gov ↗ What to watch
September 2030 (1) Deulumateperone Phase 3 Generalized Anxiety Disorder Est. primary completion 2030-09-20 ·
NCT07856420 ·
CT.gov ↗ What to watch
2031 (1) 2032 (1) April 2032 (1) Lumateperone · Caplyta Phase 3 Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder Est. primary completion 2032-04-28 ·
NCT06229210 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Regulatory and conference events (5) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
21 September 2026 Topline result Lumateperone Study 451 phase 3 topline 27 April 2026 Approval Lumateperone FDA approves CAPLYTA sNDA for relapse prevention in schizophrenia 6 November 2025 Approval Lumateperone FDA approves CAPLYTA for adjunctive treatment of MDD 5 November 2025 Approval Lumateperone FDA Boxed Warning on Caplyta (NDA209500) 8 July 2025 Filing submitted Lumateperone Johnson & Johnson submits a CAPLYTA sNDA for schizophrenia relapse prevention Financial reports No financial reports recorded.